← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Immunobrain Checkpoint Inc.
New York, NY
$5,749,685
Total funding
1
Grants
Funding over time
peak $2.5M · FY2021–23$2.5M$1.9M$1.3M$625K$0
'21
'22
'23
Funding mix
By agency
NIH$5,749,685 · 1
By mechanism
R01$5,749,685 · 1
Investigators at Immunobrain Checkpoint Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
First-in-Human (Phase 1) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of IBC-Ab002 in Persons with Early Alzheimer's Disease (AD)$2,234,624
R01 · FY2022 · AG
First-in-Human (Phase 1) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of IBC-Ab002 in Persons with Early Alzheimer's Disease (AD)$1,984,624
R01 · FY2021 · AG
First-in-Human (Phase 1) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of IBC-Ab002 in Persons with Early Alzheimer's Disease (AD)$1,280,437
R01 · FY2023 · AG
First-in-Human (Phase 1) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of IBC-Ab002 in Persons with Early Alzheimer's Disease (AD)$250,000
R01 · FY2022 · AG